Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be in the works from Korea’s Alteogen following a licensing deal worth ...

Seeking to extend the reign of cancer king Keytruda, Merck has shown that a subcutaneous version of the anti-PD-1 therapy performs as well as the more invasive infusion formulation in a Phase III ...

Moreover, a dysfunction of the autonomic nervous system can be induced as a side effect of drug treatment interacting. When dysautonomia is prominent or compared early in the clinical course of ...